The US FDA took another less prescriptive and more descriptive approach when writing the label for Tesaro Inc.'s ovarian cancer treatment Zejula (niraparib).
US FDA Shows Relaxed Approach On Personalized Medicine In Zejula Approval
Tesaro's ovarian cancer treatment performed better in patients with BRCA mutation, but FDA did not restrict indication, leaving decision to providers.
More from Approvals
• By
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
• By
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
• By
The African Medicines Agency is to appoint a director general and become operational at the end of this month.